Taryag Medical manufactures and develops invasive vascular devices. Its first technology, the ByCross device, an alternative to bypass surgeries, restores blood flow in chronic total occlusion (CTO), with no need for a guide wire. Taryag Medical is continuously developing devices and is focused on treating peripheral vascular disease by endovascular approach. Using our accumulated experience and capabilities, clinical experts and designers are invited to develop with us more innovative technologies for overcoming challenges in vascular disease care.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Hailan 14, Or Akiva,israel
- Phone
- +972.4.6776929
- in****@****cal.com
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- taryag-medical.com
- Keywords
- Chronic total occlusion, Atherectomy, Thrombectomy, Blood clot, PAD (Peripheral arteries disease), PVD (Peripheral vascular disease), Bypass surgery, Over the wire, Aspiration, Rotational device, Remote control, Guide wire, Stent, Graft, Balloon.
- HQ
- Or Akiva
Taryag Medical Questions
Taryag Medical's helpline number is +972.4.6776929
Taryag Medical's website is taryag-medical.com
Taryag Medical's LinkedIn profile is https://il.linkedin.com/company/taryag-medical
Taryag Medical has
4 employees.
View email and phone details for 4
employees at Taryag Medical.
Taryag Medical's industry is
Medical Equipment Manufacturing
Taryag Medical's top competitors are
Tag Medical Products Corporation Ltd.,
Taryag Sterilization And Labs,
Pulsenmore,
Forsight Robotics,
Plus Medica,
Plus Medica Ag,
Bioprotect Ltd,
Lts Device Technologies,
Rogel-Avital Engineering,
Initia Ltd..
Taryag Medical's support email address is info@taryag-medical.com
Taryag Medical's categories are Medical Equipment Manufacturing
Taryag Medical's founding year is 2013
